NasdaqCM:SNSS

Stock Analysis Report

Executive Summary

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers.

Snowflake

Fundamentals

High growth potential with mediocre balance sheet.

Risks

  • Sunesis Pharmaceuticals has significant price volatility in the past 3 months.

Share Price & News

How has Sunesis Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-15.0%

NasdaqCM:SNSS

0.6%

US Biotechs

0.8%

US Market


1 Year Return

-55.3%

NasdaqCM:SNSS

-10.2%

US Biotechs

1.9%

US Market

SNSS underperformed the Biotechs industry which returned -9.7% over the past year.

SNSS underperformed the Market in United States of America which returned 2.1% over the past year.


Share holder returns

SNSSIndustryMarket
7 Day-15.0%0.6%0.8%
30 Day2.4%-0.8%3.4%
90 Day25.1%-0.5%2.1%
1 Year-55.3%-55.3%-9.4%-10.2%4.2%1.9%
3 Year-80.3%-80.3%6.0%2.4%46.7%37.2%
5 Year-98.0%-98.0%5.0%-0.09%62.3%44.5%

Price Volatility Vs. Market

How volatile is Sunesis Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sunesis Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

20.45x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Sunesis Pharmaceuticals to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Sunesis Pharmaceuticals to establish if it is available at substantial discount.


Price Based on Earnings

Sunesis Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.

Sunesis Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Sunesis Pharmaceuticals, we can't assess if its growth is good value.


Price Based on Value of Assets

Sunesis Pharmaceuticals is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Sunesis Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

41.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Sunesis Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.

Sunesis Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.

Sunesis Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.

Sunesis Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.

Sunesis Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Sunesis Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Sunesis Pharmaceuticals performed over the past 5 years?

8.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Sunesis Pharmaceuticals does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Sunesis Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Sunesis Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Sunesis Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Sunesis Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Sunesis Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Sunesis Pharmaceuticals's financial position?


Financial Position Analysis

Sunesis Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Sunesis Pharmaceuticals's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Sunesis Pharmaceuticals's level of debt (46.5%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (87.8% vs 46.5% today).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 3.6x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Sunesis Pharmaceuticals has less than a year of cash runway based on current free cash flow.

Sunesis Pharmaceuticals has less than a year of cash runway if free cash flow continues to reduce at historical rates of -18.3% each year.


Next Steps

Dividend

What is Sunesis Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Sunesis Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Sunesis Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Sunesis Pharmaceuticals has not reported any payouts.

Unable to verify if Sunesis Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Sunesis Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Sunesis Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Sunesis Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

1.7yrs

Average management tenure


CEO

Dayton Misfeldt (45yo)

1.7yrs

Tenure

US$1,539,337

Compensation

Mr. Dayton Misfeldt has been an Interim CEO of Sunesis Pharmaceuticals, Inc. since January 1, 2018 and as its Director since April 2009. Mr. Misfeldt serves as Managing Director and Investment Partner at B ...


Management Age and Tenure

1.7yrs

Average Tenure

48yo

Average Age

The average tenure for the Sunesis Pharmaceuticals management team is less than 2 years, this suggests a new team.


Board Age and Tenure

10.4yrs

Average Tenure

66yo

Average Age

The average tenure for the Sunesis Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$1,500,00015 Jul 19
Aisling Capital Management LP
EntityCompany
Shares2,500,000
Max PriceUS$0.60
BuyUS$18,80012 Dec 18
William Quinn
EntityIndividual
Role
Chief Financial Officer
Senior VP of Finance & Corporate Development and CFO
Shares40,000
Max PriceUS$0.47

Ownership Breakdown


Management Team

  • Dayton Misfeldt (45yo)

    Interim CEO & Director

    • Tenure: 1.7yrs
    • Compensation: US$1.54m
  • Dan Swisher (56yo)

    Strategic Advisor

    • Tenure: 1.7yrs
    • Compensation: US$565.45k
  • Debbie Thomas

    Senior Vice President

    • Tenure: 3.6yrs
  • Judy Fox

    Chief Scientific Officer and Executive VP of Research & Development

    • Tenure: 2.7yrs
  • Willie Quinn (48yo)

    Senior VP of Finance & Corporate Development and CFO

    • Tenure: 1.8yrs
    • Compensation: US$501.17k
  • Gene Jamieson

    Vice President of Technical Operations

    • Tenure: 0yrs
  • Par Hyare

    Senior Vice President of Commercial

    • Tenure: 0.2yrs
  • Sean Gharpurey

    Executive Director of Project Management

    • Tenure: 1.2yrs
  • Steve Nava

    Vice President of Quality Assurance

    • Tenure: 1.2yrs

Board Members

  • Dave Stump (69yo)

    Independent Director

    • Tenure: 13.3yrs
    • Compensation: US$92.74k
  • Jim Young (74yo)

    Non-Executive Chairman

    • Tenure: 15.8yrs
    • Compensation: US$105.24k
  • Dayton Misfeldt (45yo)

    Interim CEO & Director

    • Tenure: 1.7yrs
    • Compensation: US$1.54m
  • Henry Wolff (70yo)

    Director

    • Tenure: 1.6yrs
    • Compensation: US$276.08k
  • Steve Ketchum (54yo)

    Independent Director

    • Tenure: 7.6yrs
    • Compensation: US$87.74k
  • Homer Pearce (66yo)

    Independent Director

    • Tenure: 13.3yrs
    • Compensation: US$99.62k
  • Steve Carchedi (57yo)

    Director

    • Tenure: 6.3yrs
    • Compensation: US$110.24k

Company Information

Sunesis Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sunesis Pharmaceuticals, Inc.
  • Ticker: SNSS
  • Exchange: NasdaqCM
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$94.622m
  • Shares outstanding: 111.32m
  • Website: https://www.sunesis.com

Number of Employees


Location

  • Sunesis Pharmaceuticals, Inc.
  • 395 Oyster Point Boulevard
  • Suite 400
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
A2ARHWDB (Deutsche Boerse AG)COM PAR USD0.0001 (POST REV SPLT)DEEURNo data
SNSSNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDSep 2005
RYIPDB (Deutsche Boerse AG)YesCommon StockDEEURSep 2005

Biography

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is v ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/17 23:52
End of Day Share Price2019/09/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.